Business
INVO Bioscience Announces Pricing of $4.5 Million Public Offering
SARASOTA, Fla., Aug. 4, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., Aug. 4, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq:INVO) (\"INVO\" or the \"Company\"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (\"IVC\") procedure it enables, today announced the pricing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock. Each unit is being sold at a public offering price of $2.85. The warrants will be immediately exercisable at a price of $2.85 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.\n\n \n \n \n \n \n \n\n \nGross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $4.5 million. The offering is expected to close on August 8, 2023, subject to customary closing conditions.\nMaxim Group LLC is acting as sole placement agent in connection with this offering.\nThe securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-273174) (the \"Registration Statement\"), which was declared effective by the Securities and Exchange Commission (the \"SEC\") on August 3, 2023. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to this offering, when available, will be filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.\nAbout INVO Bioscience\nWe are a healthcare services fertility company dedicated to expanding the assisted reproduct...